NeurogesX Submits NDA For NGX-4010 Dermal Capsaicin Patch For Treatment Of Postherpetic Neuralgia (PHN)

NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has submitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for approval to market its investigational product candidate, NGX-4010, for the management of pain due to postherpetic neuralgia (PHN).

More: continued here

Filed under: Pain / Anesthetics on October 27th, 2008